Why the study?
Does Danshen protect against adriamycin-induced cardiac and hepatic toxicity in Wistar rats?
Does Danshen protect against adriamycin-induced cardiac and hepatic toxicity in Wistar rats?
Danshen demonstrates potential protective effects against adriamycin-induced cardiotoxicity and hepatotoxicity in a preclinical rat model.
Answers are grounded in this paper and cite their sources.
Clinical use of Danshen for ADR toxicity unsupported; leaves open translation from rat cardioprotection data.
The present study was carried out to investigate the protective effects of Danshen (DS, Salvia miltiorrhiza) on adriamycin (ADR)-induced cardiac and hepatic toxicity. Wistar rats were divided into six groups: control group, 10 animals received saline (i.p.); 15 animals received ADR (3 mg/kg, i.p.) three times weekly, for 2 weeks; 10 animals each received DS(1) (20 mg/kg, oral) and DS(2) (100 mg/kg, oral) for 30 days; 15 animals each received DS(1) + ADR and DS(2) + ADR. The ADR-induced cardiac and hepatic toxicity and protective action of DS were determined and quantitated with the use of hemodynamic measurements, biochemical analyses of serum, synthesis rates of DNA, RNA and protein, myocardial antioxidants, lipid peroxidation and histopathological procedure. Liver function was damaged. Nucleic acid as well as protein synthesis was inhibited, while lipid peroxidation was increased. Myocardial glutathione peroxidase (GSHPx) activity and superoxide dismutase activities (SOD) were decreased and histopathology revealed myocardial lesions indicative of ADR-induced cardiac and hepatic toxicity. In contrast, administration of DS before and concurrent with ADR significantly attenuated these effects. In conclusion, DS is potentially protective against ADR-induced cardiac and hepatic toxicity.
No takes yet. Share an insight, caveat, or question.
You et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: